MX2018012471A - Metodos de diagnostico y terapeuticos para el cancer. - Google Patents
Metodos de diagnostico y terapeuticos para el cancer.Info
- Publication number
- MX2018012471A MX2018012471A MX2018012471A MX2018012471A MX2018012471A MX 2018012471 A MX2018012471 A MX 2018012471A MX 2018012471 A MX2018012471 A MX 2018012471A MX 2018012471 A MX2018012471 A MX 2018012471A MX 2018012471 A MX2018012471 A MX 2018012471A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- methods
- patient
- diagnostic
- therapeutic methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente invención provee métodos de diagnóstico y terapéuticos y composiciones para el cáncer. La invención provee métodos para determinar si es probable que un paciente que tiene un cáncer responda al tratamiento que comprende un inhibidor de la señalización de MAPK, métodos para predecir la capacidad de respuesta de un paciente que tiene un cáncer al tratamiento que comprende uno o más inhibidores de la señalización de MAPK, métodos para seleccionar una terapia para un paciente que tiene un cáncer, y métodos para tratar el cáncer según los niveles de expresión de los biomarcadores de la invención (p. ej., los niveles de expresión de DUSP6, ETV4, SPRY2, SPRY4, PHLDA1, ETV5, DUSP4, CCND1, EPHA2, y EPHA4).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323210P | 2016-04-15 | 2016-04-15 | |
PCT/US2017/026941 WO2017180581A1 (en) | 2016-04-15 | 2017-04-11 | Diagnostic and therapeutic methods for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012471A true MX2018012471A (es) | 2019-02-21 |
Family
ID=58606578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012471A MX2018012471A (es) | 2016-04-15 | 2017-04-11 | Metodos de diagnostico y terapeuticos para el cancer. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20190032150A1 (es) |
EP (1) | EP3443114A1 (es) |
JP (1) | JP2019518426A (es) |
KR (1) | KR20180134347A (es) |
CN (1) | CN109072311A (es) |
AU (1) | AU2017249229A1 (es) |
CA (1) | CA3018406A1 (es) |
IL (1) | IL262208A (es) |
MX (1) | MX2018012471A (es) |
WO (1) | WO2017180581A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
JP7379355B2 (ja) | 2017-11-20 | 2023-11-14 | トルレモ セラピューティクス アーゲー | 診断方法 |
WO2020046966A1 (en) * | 2018-08-27 | 2020-03-05 | Kura Oncology, Inc. | Treatment of adenocarcinomas with mapk pathway inhibitors |
CN109609640A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院上海高等研究院 | Etv4的用途 |
US20220160714A1 (en) * | 2019-03-22 | 2022-05-26 | Icahn School Of Medicine At Mount Sinai | Methods for treating colorectal cancer |
CN109925316B (zh) * | 2019-03-26 | 2021-09-14 | 广州医科大学附属第二医院 | 一种治疗溃疡性结肠炎的药物 |
KR20220159289A (ko) | 2021-05-25 | 2022-12-02 | 주식회사 박셀바이오 | 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포 |
CN113318105B (zh) * | 2021-05-31 | 2023-02-03 | 新乡医学院 | 含Binimetinib的用于治疗结肠癌的药物组合物及其应用 |
WO2022255401A1 (ja) * | 2021-06-03 | 2022-12-08 | 国立大学法人 東京大学 | Erk-mapk経路の異常な活性化に伴い発現する疾患マーカー |
CN114085909A (zh) * | 2021-11-09 | 2022-02-25 | 重庆医科大学 | Top1作为***标志物和/或治疗靶点的应用 |
KR20230119346A (ko) | 2022-02-07 | 2023-08-16 | 한국화학연구원 | 흑색종 치료 내성 예측용 trim51 바이오마커 및 이의 용도 |
WO2023219443A1 (ko) * | 2022-05-11 | 2023-11-16 | 동아대학교 산학협력단 | 방광암의 전이성 바이오마커 |
CN115993455A (zh) * | 2022-12-29 | 2023-04-21 | 南京医科大学康达学院 | Rna结合蛋白nova2作为非小细胞肺癌转移标志物的应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
EP0772609B1 (en) | 1994-07-21 | 1999-02-24 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
US6140332A (en) | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2288705C (en) | 1997-05-06 | 2008-03-18 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
TWI522337B (zh) | 2005-06-22 | 2016-02-21 | 普雷辛肯公司 | 用於激酶調節的化合物及方法及其適應症 |
DK1934174T3 (da) | 2005-10-07 | 2011-08-01 | Exelixis Inc | Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme |
US7812143B2 (en) * | 2006-03-31 | 2010-10-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for cancer treatment |
BRPI0714629A2 (pt) | 2006-08-21 | 2013-05-07 | Genentech Inc | composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas |
WO2008024725A1 (en) | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
BRPI0716944A2 (pt) * | 2006-09-19 | 2013-09-17 | Novartis Ag | biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf |
JP5211063B2 (ja) | 2006-11-30 | 2013-06-12 | ジェネンテック, インコーポレイテッド | アザ−インドリル化合物及び使用方法 |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
EP1980627A1 (en) * | 2007-04-13 | 2008-10-15 | Pangaea Biotech, S.A. | Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression |
WO2008157179A2 (en) | 2007-06-12 | 2008-12-24 | Genentech, Inc. | N-substituted azaindoles and methods of use |
US20130331294A1 (en) * | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
CA2704125A1 (en) | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
CN101945870B (zh) | 2007-12-19 | 2012-10-03 | 健泰科生物技术公司 | 5-苯氨基咪唑并吡啶和使用方法 |
US8486963B2 (en) | 2007-12-21 | 2013-07-16 | Genentech, Inc. | Azaindolizines and methods of use |
MX2010014559A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Heterociclos bicíclicos sustituidos y metodos de uso. |
US8492427B2 (en) | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
MX339873B (es) | 2011-02-28 | 2016-06-15 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
ES2552989T3 (es) | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
SG11201402765TA (en) | 2011-12-30 | 2014-06-27 | Hanmi Pharm Ind Co Ltd | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
CN104203268A (zh) * | 2012-01-13 | 2014-12-10 | 霍夫曼-拉罗奇有限公司 | 用于识别适于用vegf拮抗剂治疗的患者的生物标记物 |
CN106349217B (zh) | 2012-03-01 | 2020-08-28 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
CN105143200B (zh) | 2012-08-27 | 2018-10-16 | 阵列生物制药公司 | 用于治疗过度增殖性疾病的丝氨酸/苏氨酸激酶抑制剂 |
JP2015533151A (ja) | 2012-10-16 | 2015-11-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | セリン/スレオニンキナーゼ阻害剤 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
WO2014152377A1 (en) * | 2013-03-14 | 2014-09-25 | Vanderbilt University | Methods for classifying and treating adenocarcinomas |
US10968484B2 (en) * | 2013-03-15 | 2021-04-06 | The Broad Institute, Inc. | Methods of identifying responses to map kinase inhibition therapy |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US9867833B2 (en) | 2013-12-06 | 2018-01-16 | Genentech, Inc. | Serine/threonine kinase inhibitors |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
CN105980387B (zh) | 2013-12-30 | 2019-04-19 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
EP3089788B1 (en) | 2013-12-30 | 2018-10-24 | Genentech, Inc. | Serine/threonine kinase inhibitors |
BR122020014933B8 (pt) | 2014-04-09 | 2022-12-13 | Genentech Inc | Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico |
-
2017
- 2017-04-11 CA CA3018406A patent/CA3018406A1/en active Pending
- 2017-04-11 JP JP2018554110A patent/JP2019518426A/ja active Pending
- 2017-04-11 AU AU2017249229A patent/AU2017249229A1/en not_active Abandoned
- 2017-04-11 CN CN201780022836.3A patent/CN109072311A/zh active Pending
- 2017-04-11 KR KR1020187029434A patent/KR20180134347A/ko not_active Application Discontinuation
- 2017-04-11 WO PCT/US2017/026941 patent/WO2017180581A1/en active Application Filing
- 2017-04-11 EP EP17718767.1A patent/EP3443114A1/en not_active Withdrawn
- 2017-04-11 MX MX2018012471A patent/MX2018012471A/es unknown
-
2018
- 2018-10-08 IL IL262208A patent/IL262208A/en unknown
- 2018-10-11 US US16/157,582 patent/US20190032150A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2019518426A (ja) | 2019-07-04 |
CN109072311A (zh) | 2018-12-21 |
IL262208A (en) | 2018-11-29 |
AU2017249229A1 (en) | 2018-10-04 |
CA3018406A1 (en) | 2017-10-19 |
KR20180134347A (ko) | 2018-12-18 |
EP3443114A1 (en) | 2019-02-20 |
WO2017180581A8 (en) | 2018-05-03 |
WO2017180581A1 (en) | 2017-10-19 |
US20190032150A1 (en) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012471A (es) | Metodos de diagnostico y terapeuticos para el cancer. | |
PH12018502355A1 (en) | Enzyme inhibitors | |
WO2020121310A3 (en) | Method of treating cancer with a cancer therapy in combination with another therapeutic agent | |
MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
MX2020002553A (es) | Metodos de diagnostico y terapeuticos para el cancer. | |
MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
EP4085919A3 (en) | Compositions and methods to treat cancer | |
MX2018008169A (es) | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. | |
BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
CY1123033T1 (el) | Σπειροκυκλικοι αναστολεις της καθεψινης c | |
EA201791095A1 (ru) | Способ лечения рака | |
BR112018007656A2 (pt) | terapia de combinação para tratamento de doenças malignas | |
WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
EA201892803A1 (ru) | Противоопухолевая терапия | |
TR201905233T4 (tr) | Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi. | |
BR112018001438A2 (pt) | expressão de fgfr e suscetibilidade a um inibidor de fgfr | |
MX362806B (es) | Inhibidores biciclicos. | |
MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
MX2017015922A (es) | Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos. | |
BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
MX2022012386A (es) | Compuestos inhibidores de metaloenzimas. |